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Objectives: Low	ultraviolet-	B	 (UVB)	 radiation	causes	hypovitaminosis	D,	which	 is	a	
known	risk	factor	for	multiple	sclerosis	(MS)	and	associated	with	MS	disease	activity.	
Our objective is to test whether vitamin D supplementation is most effective in lower-
ing	disease	activity	during	the	period	of	the	year	with	low	UVB	radiation	and	conse-
quently	low	serum	25-	hydroxyvitamin	D3	(25(OH)D3)	concentration.










by	 the	prominent	 reduction	 in	 the	quarterly	 relapse	 rate	 in	 late	winter/early	 spring,	
when	25(OH)D3 levels of nonsupplemented patients were the lowest.
Conclusions: Our	study	demonstrated	the	modulation	of	seasonal	MS	disease	activity	
through vitamin D supplementation. Given the prominent reduction in the quarterly 
relapse	rate	in	late	winter/early	spring,	our	data	indicate	a	beneficial	effect	of	supple-
menting	MS	patients	with	vitamin	D,	especially	during	this	period	of	the	year.




nervous system and one of the most frequent neurological disorders 
in	young	adults	(Noseworthy,	Lucchinetti,	Rodriguez,	&	Weinshenker,	
2000).	 The	 generally	 recognized	 MS	 risk	 factor	 hypovitaminosis	 D	
(Ascherio	&	Munger,	2007;	Hanwell	&	Banwell,	 2011)	 is	defined	as	
a	 25-	hydroxyvitamin	 D	 (25(OH)D)	 concentration	 below	 50	nmol/L	
and	is	prevalent	in	approximately	57%	of	German	adults	(Hintzpeter,	
Mensink,	 Thierfelder,	 Müller,	 &	 Scheidt-	Nave,	 2008).	 Experimental	
data	 show	 that	 vitamin	 D	 (VD)	 possesses	 anti-	inflammatory	 and	
immunomodulatory properties through inhibition of dendritic cell 
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differentiation,	induction	of	T	regulatory	cells,	blockage	of	Th17	differ-
entiation,	and	down-	regulation	of	Th1	immune	responses	(Farias	et	al.,	
2013;	 Hamzaoui	 et	al.,	 2014;	 Lemire,	 Archer,	 Beck,	 &	 Spiegelberg,	
1995).	Concordantly,	 several	 studies	have	 found	an	 inverse	 correla-
tion	 between	 serum	25(OH)D	 concentration	 and	 disease	 activity	 in	
MS	patients	 (Brola	et	al.,	2016;	Pierrot-	Deseilligny,	Rivaud-	Péchoux,	
Clerson,	de	Paz,	&	Souberbielle,	2012;	Rotstein	et	al.,	2015;	Simpson	




greater	 distance	 from	 the	 equator,	 is	mandatory	 for	 the	 conversion	





and	UVB	 radiation	 (Orton	et	al.,	 2011).	While	UVB	 radiation	 is	 also	
thought	to	have	a	VD	independent	immunomodulatory	effect	(Breuer	
et	al.,	2014),	it	contributes	to	approximately	90%	of	the	body’s	25(OH)
D	supply	 (Federal	Office	 for	Radiation	Protection	 (Germany),	2012).	
Ascherio	et	al.	 reported	a	57%	 lower	 relapse	 rate	 in	patients	with	a	
higher	 25(OH)D	 concentration	 (Ascherio	 et	al.,	 2014).	 Furthermore,	
an	 analysis	 of	 the	 international	MSBase	 registry	 data	 demonstrated	








D has the most substantial impact on the immune system in late win-
ter/early spring.
To	our	knowledge	no	other	study	has	yet	examined	 the	 interac-




D3	 levels	are	 low.	 If	this	 increase	 in	MS	disease	activity	 is	genuinely	
induced	by	hypovitaminosis	D,	 then	VD	supplementation	 should	be	
most effective during this period of the year.
2  | METHODS
2.1 | Patient group studied
Our	 retrospective	 medical	 chart	 analysis	 identified	 40	 MS	 patients	
with an observation period of at least 6 months before and after the 
initiation	of	VD	supplementation.	All	patients	were	 treated	between	
April	2010	and	June	2016	at	the	neurological	outpatient	department	
Neurocenter	 Peine,	 in	 Peine	 (latitude	 52.3,	 longitude	 10.2),	 Lower	
Saxony,	 Germany.	 Unless	 contraindicated,	 generally	 all	 MS	 patients	
from our outpatient department are recommended to take orally 
20,000	international	units	(IU)	of	VD	per	week.	This	is	well	below	the	
Food	and	Nutrition	Board’s	upper	tolerable	intake	limit	recommenda-
tion	 of	 4,000	IU/day	 (28,000	IU/week)	 (Institute	 of	Medicine,	 Food	
and	Nutrition	Board,	2010).	Patient	consultation	and	documentation	
was conducted by MM. Data were retrospectively assessed by MM 
and	AM.	VD	status	was	determined	by	measuring	the	serum	25(OH)
D3 concentration in a local laboratory using chemiluminescent immu-
noassay. If different immunotherapies were used in the predefined 
intervals	 (before	 and	 during	 VD	 supplementation),	 the	 MS	 therapy	






We	 received	 the	 local	 (latitude	52.2,	 longitude	9.1)	 erythemal	UVB	






Efficacy	 endpoints	 were	 the	 individually	 analyzed	 quarterly	 (QRR)	
and	 annualized	 relapse	 rate	 (ARR).	 The	 ARR	was	 calculated	 by	 di-
viding the total number of relapses by the observed time in years. 
Calculation	 of	 the	 QRR	 was	 based	 on	 the	 monthly	 relapse	 rates,	
which were calculated by dividing the cumulative number of relapses 







radiation.	Regarding	the	comparison	of	serum	25(OH)D3 levels before 
and	during	VD	supplementation,	we	followed	Hintzpeter	et	al.’s	pro-






and	 QRR	 before	 and	 during	 VD	 supplementation.	 Statistical	 signifi-
cance was declared for p	<	.05	and	illustrated	in	the	figures	using	“*”.	 
A	p-	value	<	.01	was	depicted	as	“**”.	All	analyses	were	performed	using	
SPSS	Statistics	20®	(IBM	Corporation:	Armonk,	New	York,	USA).
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2.5 | Ethical approval
The present retrospective data analysis was in accordance with the 
ethic	committee	of	the	medical	association	of	Lower	Saxony,	Germany.
3  | RESULTS
The baseline characteristics of the study population are presented 
in	 Table	1.	 The	 serum	 samples	 of	 25(OH)D3 measurements were 
obtained	2	years	(mean,	SD	1)	after	the	initiation	of	VD	supplemen-










September	 (Figure	S1),	which	 labels	 the	end	of	 the	period	of	high	
UVB	exposure	(Figure	S1).	This	was	the	only	period	of	the	year	dur-
ing	 which	 serum	 25(OH)D3	 levels	 of	 non-	supplemented	 patients	
were	above	the	lower	limit	of	normal	(50	nmol/L	(Hintzpeter	et	al.,	
2008)).	 In	 contrast,	 during	VD	 supplementation,	 serum	25(OH)D3 
levels	 remained	 steadily	 above	 70	nmol/L	 and	 the	 seasonal	 fluc-
tuations	 ceased	 (Figure	1).	 The	 correlation	 between	 UVB	 radia-
tion	and	serum	25(OH)D3 concentration was no longer significant 
(rho	=	−0.13,	p	=	.33,	number	of	25(OH)D3	measurements:	62).
In	 comparison	 to	before	 supplementation,	 the	ARR	was	 approxi-
mately	50%	lower	during	VD	supplementation	(Figure	2a),	which	was	
driven by the significantly lower QRR in the first quarter of the year 
(January–March)	(Figure	2b).	Before	VD	supplementation,	also	the	low-
est	serum	25(OH)D3	levels	were	measured	in	the	period	from	January	
to	 March	 (Figure	1).	 By	 excluding	 this	 period	 from	 the	 relapse	 rate	
calculation,	 the	 difference	 in	 relapse	 rates	was	 no	 longer	 significant	







Investigating	 the	 effect	 of	 VD	 supplementation	 on	 the	 interactions	
between	 seasonal	 variations	 in	 UVB	 radiation,	 serum	 25(OH)D3 
TABLE  1 Baseline	characteristics
Baseline characteristics Mean SD N
Age	at	MS	diagnosis	(in	years) 33.9 11.8 40




EDSS	score	at	start	of	VD	supplementation 3.1 1.5 39
VD	dose	(in	international	units/week) 18,950 3,397 40
Gender % N
Female 60 — 24
MS	phenotype % N
RRMS 75 — 30
PRMS 25 — 10









Interferons 35% 30% n.s.c
No therapy 30% 22.5% n.s.c
Glatiramer acetate 17.5% 20% n.s.c
Natalizumab 10% 17.5% n.s.c
Immunosuppressants 5% 2.5% n.s.c
Glucocorticoids 2.5% 2.5% n.s.c
Dimethyl fumarate 0% 5% n.s.cs
EDSS,	 Expanded	 disability	 status	 scale;	 MS,	 Multiple	 sclerosis;	 n.s.,	
Nonsignificant;	 PR,	 Progressive	 relapsing;	 RR,	 Relapsing	 remitting;	 VD,	
Vitamin	D;	25(OH)D3,	25-	hydroxyvitamin	D3.
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concentration,	and	MS	disease	activity,	we	demonstrated	that	relapse	
rates were higher and more subject to seasonal fluctuations before 
the	 supplementation	 with	 VD.	 VD	 supplementation	 had	 the	 great-
est	effect	on	relapse	rates	in	the	first	quarter	of	the	year,	when	UVB	 
radiation	 and	 consequently	 25(OH)D3 levels of nonsupplemented 
patients were low.
Through	 oral	 supplementation	 with	 VD	 (18,950	IU	 per	 week	
[mean,	 SD	 3,397]),	 serum	 25(OH)D3 levels increased significantly 
by	 approximately	 51	nmol/L	 (Table	1).	 Similarly,	 a	 prospective	 co-
hort	 study	 from	 Finland	 reported	 an	 increase	 of	 56	nmol/L	 after	
supplementing	patients	with	20,000	IU	of	VD	per	week	for	12	months	
(Soilu-	Hänninen	et	al.,	2012).
In	 our	 study	 cohort,	 the	ARR	 decreased	 by	 approximately	 50%	
after	the	initiation	of	VD	supplementation.	In	comparison,	Burton	et	al.	






F IGURE  2 Relapse rates before and 
during	vitamin	D	supplementation.	(a)	



















































































































* n.s. n.s. n.s.
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therefore the major weakness of our study and should be considered 
while interpreting the epidemiological data.
Before	VD	 supplementation,	 patients	 also	 demonstrated	 a	 peak	
of	relapse	rates	from	July	to	September,	which	was	not	paralleled	by	






immunological	modulations,	 in	 particularly	 to	 a	 change	 in	 leukocyte	
nitric-	oxide	production	(Beenakker	et	al.,	2001;	Oqawa	et	al.,	2004).	A	
complementary	immunological	explanation	from	a	recently	conducted	
study	 are	 the	 summer	 troughs	 of	melatonin	 production,	which	 ulti-
mately	 lead	 to	 the	 induction	of	pathogenic	Th17-	cell	differentiation,	
inhibition	 of	 protective	 T-	regulatory	 cells,	 and	 deactivation	 of	 IL-	10	
promotors	(Farez	et	al.,	2015).	Further	studies	are	warranted	to	clarify	
these hypotheses as possible reasons for the increase in relapse rates 
during summer.



















radiation	contributes	 to	approximately	90%	of	 the	body’s	25(OH)D3 
supply	(Federal	Office	for	Radiation	Protection	(Germany),	2012),	we	
conclude	that	seasonal	UVB	radiation	has	a	stronger	impact	on	serum	
25(OH)D3 levels than the effects caused by each individual patient. 
Our conclusion is supported by a correlation analysis between the 
mean	values	of	serum	25(OH)D3	levels	and	the	mean	concurrent	UVB	
radiation,	which	precludes	 the	 inclusion	of	more	 than	one	observa-
tion	per	patient	(prior	VD	supplementation:	rho	=	0.42,	p	=	.01,	n	=	35;	
during	VD	supplementation:	rho	=	−0.24,	p	=	.19,	n	=	32).	Lastly,	 im-










tation studies should adjust their efficacy analysis for the different 
seasons	of	the	year.	Furthermore,	future	research	should	focus	on	the	
identification	 of	 additional	 triggering	 factors	 of	MS	disease	 activity.	
Ideally—as	 is	 the	 case	 with	 VD—these	 factors	 could	 be	 modulated	
therapeutically.	 In	addition	to	standard	medication,	 this	would	allow	
supportive therapies adjusted for the specific immunological demands 




providing the regional climate data.
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